|Bid||81.26 x 3100|
|Ask||81.17 x 1100|
|Day's range||76.85 - 83.20|
|52-week range||12.52 - 105.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||61.97|
During BioNTech's (BNTX) upcoming Q2 earnings conference, investors will keep track of the advancement of its COVID-19 vaccine candidate being developed in partnership with Pfizer.
The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech
Canada has signed separate deals with Pfizer Inc <PFE.N> and Moderna Inc <MRNA.O> to supply millions of doses of their experimental coronavirus vaccines, a top official said on Wednesday. Procurement Minister Anita Anand said Ottawa was "very, very intensely negotiating" multiple deals with a number of other potential domestic and international vaccine suppliers, but did not give details. There are no approved vaccines for COVID-19, but 19 vaccines are being tested in humans around the world.